SCHEMBL6158655

SCHEMBL6158655

CCOC(=O)CCC(=O)c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 3/20 0.58
PLOD2 O00469 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GAA P10253 2/20 0.51
ALDH1A1 P00352 3/20 0.50
HDAC1 Q13547 1/20 0.50
MAPT P10636 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
TP53 P04637 1/20 0.49
LMNA P02545 2/20 0.49
CTNNB1 P35222 1/20 0.49
WNT3A P56704 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 1/20 0.48
PLOD3 O60568 1/20 0.47
PLOD1 Q02809 1/20 0.47
APP P05067 1/20 0.46
HCAR3 P49019 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11375570 0.98 TBXAS1 (0.57) TBXAS1PLOD2L3MBTL1GAAALDH1A1
SCHEMBL81386 0.86 PLOD2 (0.61) TBXAS1PLOD2L3MBTL1GAAALDH1A1
SCHEMBL7495118 0.86 L3MBTL1 (0.68) TBXAS1PLOD2L3MBTL1ALDH1A1HDAC1
SCHEMBL30109394 0.84 ALDH1A1 (0.60) TBXAS1PLOD2GAAALDH1A1HDAC1
SCHEMBL6863607 0.84 ALDH1A1 (0.60) TBXAS1PLOD2GAAALDH1A1HDAC1
SCHEMBL7075878 0.83 PLOD2 (0.69) TBXAS1PLOD2GAAALDH1A1HDAC1
SCHEMBL28958982 0.83 TBXAS1 (0.57) TBXAS1L3MBTL1GAAALDH1A1MAPT
SCHEMBL30421819 0.83 TBXAS1 (0.57) TBXAS1L3MBTL1GAAALDH1A1MAPT
SCHEMBL7661524 0.82 PLOD2 (0.56) TBXAS1PLOD2L3MBTL1GAAALDH1A1
SCHEMBL6160053 0.81 ALDH1A1 (0.48) PLOD2L3MBTL1GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10639300-B2 Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists SOLIS HERRERA ARTURO (MX) 2020-05-05 US disclosed
US-20190111038-A1 COMPOSITIONS AND METHODS FOR TREATING NASAL AND PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS SOLIS HERRERA ARTURO (MX) 2019-04-18 US disclosed
EP-3442583-A2 COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS Solis Herrera, Arturo (MX) 2019-02-20 EP disclosed
WO-2017178897-A2 COMPOSITIONS AND METHODS FOR TREATING PARANASAL MUCOSA DISEASES WITH NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS SOLIS HERRERA ARTURO (MX) 2017-10-19 WO disclosed
US-6924300-B2 Oxyiminoalkanoic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
EP-1077957-B1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-08-04 EP disclosed
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP disclosed
CN-1148361-C Oxyiminoalkanoic acid derivatives ����ҩƷ��ҵ��ʽ���� 2004-05-05 CN disclosed
US-20030186985-A1 Oxyiminoalkanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
US-6495581-B1 DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-12-17 US disclosed
EP-1240144-A2 COMPOUND HAVING EFFECT OF PROMOTING NEURON DIFFERENTIATION NIPPON KAYAKU CO., LTD. (JP) 2002-09-18 EP disclosed
US-6399606-B1 3-(((2R)-2-(((2-FLUOROPHENYL)AMINO)CARBONYLAMINO)-2-(METHOXY CARBONYL)ETHYLTHIO)METHYL)-4-OXO-4-(3-PYRIDYL)BUTANOIC ACID; TREATMENT OF CHEMOTHERAPY INDUCED NEUROPATHY NIPPON KAYAKU CO., LTD. (JP) 2002-06-04 US disclosed
US-6251926-B1 OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
CN-1300285-A Hydroxyiminoalkanoic Acid Derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-06-20 CN disclosed
WO-2001040187-A2 COMPOUND HAVING EFFECT OF PROMOTING NEURON DIFFERENTIATION NIPPON KAYAKU CO., LTD. (JP) 2001-06-07 WO disclosed
EP-1077957-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
WO-1999058510-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186985-A1 Oxyiminoalkanoic acid derivatives GPR119, IRS1, CPT1A TBXAS1 3106/4885PLOD2 1423/4885L3MBTL1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.